Keryx Biopharma - KERX

oggi si va sull'ottovolante ?!?

1253104801keryx.jpg
 
l'annuncio per ora lo fa solo AEZS

http://www.tradingmarkets.com/.site/news/Stock News/2530151/


AEZS/KERX: Orphan Drug Designation for Perifosine in Multiple Myeloma
Wed. September 16, 2009; Posted: 08:40 AM

Ridgeland, MS, SEP 16, 2009 (EventX/Knobias.com via COMTEX) -- By Fain Hughes, fhughes@knobias.com

AEterna Zentaris Inc. (AEZS) announced that Keryx Biopharmaceuticals, Inc. (KERX), its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. FDA for the treatment of multiple myeloma. In August, Keryx announced that it had reached agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial with perifosine in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.

KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.

If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com

Knobias.com, LLC
601-978-3399
601-978-3675
info@knobias.com
www.knobias.com/cmtx
For full details on Aeterna Zentaris Inc New (AEZS) click here. Aeterna Zentaris Inc New (AEZS) has Short Term PowerRatings of 4. Details on Aeterna Zentaris Inc New (AEZS) Short Term PowerRatings is available at This Link
 

Users who are viewing this thread

Back
Alto